
iwAL 2023 Session II: Novel treatments in AML: FLT3 inhibitors, combinations, and more
VJHemOnc Podcast
00:00
Mutations in ELN 2022, CPX351, and Challenges in HM-A-Venn
Discussion on MDS-related mutations in ELN 2022, including RUNKS-1 and its poor prognosis association. Highlighting the survival benefit of CPX351 compared to other chemotherapy regimens and the need for further investigation.
Transcript
Play full episode